Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open-label, Efficacy and Safety Study of Velaglucerase Alfa Enzyme Replacement Therapy in Children and Adolescents With Type 3 Gaucher Disease

NCT01685216 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT01685216
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01685216 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open-label, Efficacy and Safety Study of Velaglucerase Alfa Enzyme Replacement Therapy in Children and Adolescents With Type 3 Gaucher Disease
Lead sponsor
Shire
Phase
Phase 1/2
Overall status
Completed
Start date
September 14, 2012
Completion date
March 15, 2015
Enrollment
7 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

gaucher disease, type 3